Medivation pushes Xtandi to out-do J&J’s Zytiga in prostate cancer
This article was originally published in Scrip
Medivation says it sees the best commercial opportunity with its new prostate cancer drug Xtandi (enzalutamide) in the "pre-chemo label", which is currently being studied in the Phase III PREVAIL study. This may allow the company to work around an apparent obstruction to the drug's progress, the prior presence on the market of J&J's Zytiga (abiraterone).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.